{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:16:02Z","timestamp":1788243362478,"version":"build-2803163510"},"reference-count":120,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background: Renal Cell Carcinoma (RCC) primarily affects older adults, with incidence increasing with age. Older adults remain underrepresented in clinical trials, and treatment decisions are often extrapolated from younger populations. Age-related factors such as comorbidities, frailty, polypharmacy, and immunosenescence complicate management in the geriatric population. Methods: A narrative review of the literature was conducted, focusing on localized and metastatic RCC in older adults. The review comprehensively examined the following topics: surgical interventions, active surveillance strategies, systemic therapies (including immune checkpoint inhibitors, vascular endothelial growth factor tyrosine kinase inhibitors, and hypoxia-inducible factor-2\u03b1 (HIF-2\u03b1) inhibitors), toxicity profiles, and real-world outcomes. Results: Managing RCC in older adults requires balancing efficacy with tolerability. For localized disease, surveillance and minimally invasive approaches are suitable given mortality risks. In metastatic RCC, immune checkpoint inhibitor combinations and targeted therapies have improved outcomes, though toxicity may increase in frail patients. Given the favorable safety profile of HIF-2\u03b1 inhibitors, these agents may play a more substantial clinical role and offer improved therapeutic utility in this patient population. Real-world data show disparities between trial populations and practice, highlighting the need for individualized treatment. Conclusions: RCC management in geriatric patients requires a shift from age-based to frailty-informed decisions. Integrating geriatric assessment enables better patient selection and treatment tailoring. Future research should focus on geriatric-adapted trials, biomarker strategies, and de-escalation approaches to improve outcomes while reducing toxicity in this population.<\/jats:p>","DOI":"10.3390\/jcm15176726","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:45:13Z","timestamp":1788241513000},"page":"6726","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Renal Cell Carcinoma in the Geriatric Population: Toward a Frailty-Adapted Therapeutic Paradigm"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2373-183X","authenticated-orcid":false,"given":"Cemile","family":"Ozsurekci","sequence":"first","affiliation":[{"name":"Division of Geriatrics, Department of Internal Medicine, Lokman Hekim University Ankara Hospital, 06930 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2040-9862","authenticated-orcid":false,"given":"Ufuk","family":"Yazar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Lokman Hekim University Ankara Hospital, 06930 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0360-7938","authenticated-orcid":false,"given":"Yusuf","family":"Acikgoz","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Lokman Hekim University Ankara Hospital, 06930 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,30]]},"reference":[{"key":"ref_1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"(2026, May 25). Kidney and Renal Pelvis Cancer\u2014Cancer Stat Facts, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/bju.70116","article-title":"Trends in treatment and survival of older vs younger patients with renal cancer between 2011 and 2022","volume":"137","author":"Yildirim","year":"2026","journal-title":"BJU Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.eururo.2025.02.020","article-title":"European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update","volume":"87","author":"Bex","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Mignozzi, S., Santucci, C., Briganti, A., Montorsi, F., La Vecchia, C., Corso, G., Negri, E., and Gandaglia, G. (2025). The global burden of kidney cancer: Trends in mortality and incidence with predictions to 2025. Eur. J. Cancer Prev.","DOI":"10.1097\/CEJ.0000000000001000"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Netti, G.S., Spadaccino, F., Lucarelli, G., Catalano, V., Checchia, A., Stasi, A., De Luca, F., Camporeale, V., Leccese, G., and Cuttano, R. (2026). Molecular Remodeling of Peritumoral Tissue in Clear Cell Renal Cell Carcinoma: Insights into Inflammaging and Prognostic Markers. Cancers, 18.","DOI":"10.3390\/cancers18030414"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e35222","DOI":"10.1097\/MD.0000000000035222","article-title":"Senescence gene expression in clear cell renal cell carcinoma: Role of tumor immune microenvironment and senescence-associated survival prediction","volume":"102","author":"Wu","year":"2023","journal-title":"Medicine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/JU.0000000000001714","article-title":"Active Surveillance for Risk Stratification of All Small Renal Masses Lacking Predefined Clinical Criteria for Intervention","volume":"206","author":"Menon","year":"2021","journal-title":"J. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.21037\/atm.2018.12.46","article-title":"Predicting aggressive behavior in small renal tumors prior to treatment","volume":"6","author":"Shapiro","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"ref_10","first-page":"13","article-title":"Active surveillance for small renal masses","volume":"14","author":"Pierorazio","year":"2012","journal-title":"Rev. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.juro.2008.06.037","article-title":"Renal Cell Carcinoma in Young and Old Patients\u2014Is There a Difference?","volume":"180","author":"Thompson","year":"2008","journal-title":"J. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.juro.2006.09.064","article-title":"Watchful Waiting for Solid Renal Masses: Insight Into the Natural History and Results of Delayed Intervention","volume":"177","author":"Kouba","year":"2007","journal-title":"J. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2165\/11592880-000000000-00000","article-title":"Systemic therapies for metastatic renal cell carcinoma in older adults","volume":"28","author":"Pal","year":"2011","journal-title":"Drugs Aging"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0009-9236(97)90166-1","article-title":"Age and cytochrome P450-linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions","volume":"61","author":"Sotaniemi","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/00130404-200511000-00004","article-title":"Physiologic Aspects of Aging","volume":"11","author":"Sawhney","year":"2005","journal-title":"Cancer J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jgo.2020.12.008","article-title":"Outcomes based on age in patients with metastatic renal cell carcinoma treated with first line targeted therapy or checkpoint immunotherapy: Older patients more prone to toxicity","volume":"12","author":"Hermansen","year":"2021","journal-title":"J. Geriatr. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.17305\/bb.2025.12687","article-title":"Frailty and survival of patients with renal cell carcinoma: A meta-analysis","volume":"25","author":"Zhang","year":"2025","journal-title":"Biomol. Biomed."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mpmed.2020.10.011","article-title":"The physiology of ageing and how these changes affect older people","volume":"49","author":"Preston","year":"2021","journal-title":"Medicine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.semradonc.2021.11.003","article-title":"Exclusion of Older Adults from Cancer Clinical Trials: Review of the Literature and Future Recommendations","volume":"32","author":"Bumanlag","year":"2022","journal-title":"Semin Radiat. Oncol."},{"key":"ref_20","first-page":"78","article-title":"Older adult participation in cancer clinical trials: A systematic review of barriers and interventions","volume":"71","author":"Sedrak","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): Long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1038\/s41591-025-03867-5","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial","volume":"31","author":"Rini","year":"2025","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.2217\/imt-2023-0039","article-title":"Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: A meta-analysis","volume":"15","author":"Yanagisawa","year":"2023","journal-title":"Immunotherapy"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s11255-024-04254-8","article-title":"Comprehensive assessment in uro-oncologic geriatric patients: Interdisciplinary management to improve survival","volume":"57","author":"Chaparro","year":"2024","journal-title":"Int. Urol. Nephrol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bjhh.2015.03.007","article-title":"Limitations of performance status assessment in elderly with acute myeloid leukemia","volume":"37","author":"Carbonell","year":"2015","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"ref_27","unstructured":"(2026, May 03). EAU Guidelines on RCC\u2014PROGNOSTIC FACTORS. Available online: https:\/\/uroweb.org\/guidelines\/renal-cell-carcinoma\/chapter\/prognostic-factors."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Magnuson, A., Sattar, S., Nightingale, G., Saracino, R., Skonecki, E., and Trevino, K.M. (2019). A Practical Guide to Geriatric Syndromes in Older Adults with Cancer: A Focus on Falls, Cognition, Polypharmacy, and Depression, American Society of Clinical Oncology Educational Book.","DOI":"10.1200\/EDBK_237641"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"102934","DOI":"10.1016\/j.jgo.2026.102934","article-title":"Geriatric assessment is the future: Retiring Karnofsky and ECOG performance status in modern cancer care","volume":"17","author":"Lichtman","year":"2026","journal-title":"J. Geriatr. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Topcu, A., Yasin, A.I., Besiroglu, M., Isleyen, Z.S., Topcu, Z.A., Simsek, M., Turk, H.M., Seker, M., and Soysal, P. (2024). Prevalence and co-incidence of geriatric syndromes according to the ECOG performance status in older cancer patients. Front Med., 11.","DOI":"10.3389\/fmed.2024.1331246"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.euo.2024.09.001","article-title":"Frailty and Renal Cell Carcinoma: Integration of Comprehensive Geriatric Assessment into Shared Decision-making","volume":"8","author":"Pecoraro","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1503\/cmaj.050051","article-title":"A global clinical measure of fitness and frailty in elderly people","volume":"173","author":"Rockwood","year":"2005","journal-title":"CMAJ"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"146","DOI":"10.23736\/S2724-6051.21.04583-3","article-title":"Impact of frailty on perioperative and oncologic outcomes in patients undergoing surgery or ablation for renal cancer: A systematic review","volume":"74","author":"Campi","year":"2022","journal-title":"Minerva Urol. Nephrol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e437","DOI":"10.1016\/S1470-2045(12)70259-0","article-title":"Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: A systematic review","volume":"13","author":"Hamaker","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in Older Adults: Evidence for a Phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"15330338251316626","DOI":"10.1177\/15330338251316626","article-title":"Prognostic Value of G8 Geriatric Screening and Meet-URO Scores in Metastatic Renal Cell Carcinoma Patients Receiving First-Line Ipilimumab-Nivolumab Combination Immunotherapy","volume":"24","author":"Nagpal","year":"2025","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"102893","DOI":"10.1016\/j.jgo.2026.102893","article-title":"Geriatric prehabilitation prior to surgery for kidney tumors: Study protocol for Pre-KiT\u2014A randomized controlled trial","volume":"17","author":"Lund","year":"2026","journal-title":"J. Geriatr. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/jnci\/djaf017","article-title":"Frailty and outcomes in adults undergoing systemic anticancer treatment: A systematic review and meta-analysis","volume":"117","author":"Pearce","year":"2025","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e047376","DOI":"10.1136\/bmjopen-2020-047376","article-title":"Cancer Aging Research Group (CARG) score in older adults undergoing curative intent chemotherapy: A prospective cohort study","volume":"11","author":"Ostwal","year":"2021","journal-title":"BMJ Open"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2010.12.013","article-title":"A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma","volume":"59","author":"Albrecht","year":"2011","journal-title":"Eur. Urol."},{"key":"ref_43","first-page":"78.e17","article-title":"Is partial nephrectomy safe and effective in the setting of frail comorbid patients affected by renal cell carcinoma? Insights from the RECORD 2 multicentre prospective study","volume":"39","author":"Gontero","year":"2021","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.euf.2019.02.010","article-title":"Trifecta Outcomes of Partial Nephrectomy in Patients Over 75 Years Old: Analysis of the REnal SURGery in Elderly (RESURGE) Group","volume":"6","author":"Bindayi","year":"2020","journal-title":"Eur. Urol. Focus"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/iju.14831","article-title":"Prediction of significant renal function decline after open, laparoscopic, and robotic partial nephrectomy: External validation of the Martini\u2019s nomogram on the RECORD2 project cohort","volume":"29","author":"Antonelli","year":"2022","journal-title":"Int. J. Urol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.urology.2016.10.047","article-title":"Partial vs Radical Nephrectomy for T1-T2 Renal Masses in the Elderly: Comparison of Complications, Renal Function, and Oncologic Outcomes","volume":"100","author":"An","year":"2017","journal-title":"Urology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ejca.2014.12.012","article-title":"Overall survival and renal function after partial and radical nephrectomy among older patients with localised renal cell carcinoma: A propensity-matched multicentre study","volume":"51","author":"Chung","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"108578","DOI":"10.1016\/j.ejso.2024.108578","article-title":"Partial nephrectomy in elderly patients: A systematic review and analysis of comparative outcomes","volume":"50","author":"Lasorsa","year":"2024","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.euf.2018.01.007","article-title":"Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years","volume":"5","author":"Marchioni","year":"2019","journal-title":"Eur. Urol. Focus"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(16)00559-6","article-title":"Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): A double-blind, placebo-controlled, randomised, phase 3 trial","volume":"387","author":"Haas","year":"2016","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1056\/NEJMoa1611406","article-title":"Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy","volume":"375","author":"Ravaud","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.eururo.2020.12.029","article-title":"Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial","volume":"79","author":"Motzer","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdy454","article-title":"Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: Results from the phase III, randomized ATLAS trial","volume":"29","author":"Kwon","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1200\/JCO.20.01800","article-title":"Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial","volume":"38","author":"Eisen","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminoncol.2018.08.006","article-title":"Aging, immune senescence, and immunotherapy: A comprehensive review","volume":"45","author":"Elias","year":"2018","journal-title":"Semin Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s40425-019-0645-6","article-title":"Delayed immune-related events (DIRE) after discontinuation of immunotherapy: Diagnostic hazard of autoimmunity at a distance","volume":"7","author":"Couey","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_59","first-page":"9","article-title":"Active Surveillance for Small Renal Masses","volume":"22","author":"Ray","year":"2020","journal-title":"Rev. Urol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.juro.2017.09.087","article-title":"Growth Kinetics of Small Renal Masses on Active Surveillance: Variability and Results from the DISSRM Registry","volume":"199","author":"Uzosike","year":"2018","journal-title":"J. Urol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.juro.2010.01.024","article-title":"Active surveillance for renal cortical neoplasms","volume":"183","author":"Rosales","year":"2010","journal-title":"J. Urol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.euf.2019.06.002","article-title":"The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis","volume":"5","author":"Correa","year":"2019","journal-title":"Eur. Urol. Focus."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Suleja, A., Bilski, M., Laukhtina, E., Fazekas, T., Matsukawa, A., Tsuboi, I., Mancon, S., Schulz, R., Soeterik, T.F.W., and Przydacz, M. (2024). Stereotactic Body Radiotherapy (SBRT) for the Treatment of Primary Localized Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Cancers, 16.","DOI":"10.3390\/cancers16193276"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1470-2045(24)00020-2","article-title":"Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): A non-randomised phase 2 trial","volume":"25","author":"Siva","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(23)00513-2","article-title":"Stereotactic body radiotherapy for primary renal cell carcinoma: A systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS)","volume":"25","author":"Siva","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nrurol.2017.143","article-title":"Focal ablation therapy for renal cancer in the era of active surveillance and minimally invasive partial nephrectomy","volume":"14","author":"Ginzburg","year":"2017","journal-title":"Nat. Rev. Urol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5","DOI":"10.15586\/jkcvhl.v9i3.233","article-title":"Modern Management of Localized Renal Cell Carcinoma- Is Ablation Part of the Equation?","volume":"9","author":"Leopold","year":"2022","journal-title":"J. Kidney Cancer VHL"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e15610","DOI":"10.1097\/MD.0000000000015610","article-title":"Comparison among cryoablation, radiofrequency ablation, and partial nephrectomy for renal cell carcinomas sized smaller than 2 cm or sized 2\u20134 cm","volume":"98","author":"Yan","year":"2019","journal-title":"Medicine"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Li, L., Zhu, J., Shao, H., Huang, L., Wang, X., Bao, W., Sheng, T., Chen, D., He, Y., and Song, B. (2023). Long-term outcomes of radiofrequency ablation vs. partial nephrectomy for cT1 renal cancer: A meta-analysis and systematic review. Front Surg., 9.","DOI":"10.3389\/fsurg.2022.1012897"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"601","DOI":"10.21037\/tau.2019.10.13","article-title":"Comparative outcomes of radio frequency ablation versus partial nephrectomy for T1 renal tumors: A systematic review","volume":"8","author":"Wei","year":"2019","journal-title":"Transl. Androl. Urol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1007\/s00330-025-11480-w","article-title":"Image-guided percutaneous ablative treatments for renal cell carcinoma","volume":"35","author":"Auer","year":"2025","journal-title":"Eur. Radiol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Kawaguchi, S., Izumi, K., Naito, R., Kadomoto, S., Iwamoto, H., Yaegashi, H., Nohara, T., Shigehara, K., Yoshida, K., and Kadono, Y. (2022). Comparison of Clinical Outcomes between Robot-Assisted Partial Nephrectomy and Cryoablation in Elderly Patients with Renal Cancer. Cancers, 14.","DOI":"10.3390\/cancers14235843"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): Extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"16s","DOI":"10.1200\/JOP.19.00647","article-title":"Toxicity Management of Front-Line Pembrolizumab Combined With Axitinib in Clear Cell Metastatic Renal Cell Carcinoma: A Case Study Approach","volume":"16","author":"Wood","year":"2020","journal-title":"JCO Oncol. Pract."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Leucht, K., Ali, N., Foller, S., and Grimm, M.O. (2022). Management of Immune-Related Adverse Events from Immune-Checkpoint Inhibitors in Advanced or Metastatic Renal Cell Carcinoma. Cancers, 14.","DOI":"10.3390\/cancers14184369"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"100577","DOI":"10.1016\/j.esmoop.2022.100577","article-title":"The efficacy of immune checkpoint inhibitors in elderly patients: A meta-analysis and meta-regression","volume":"7","author":"Kim","year":"2022","journal-title":"ESMO Open"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s00262-025-04288-6","article-title":"A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: Results from the JK-FOOT consortium","volume":"75","author":"Yanagisawa","year":"2026","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(22)00212-1","article-title":"Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): A randomised, phase 3 study","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1177\/10781552221077039","article-title":"Poor tolerability of lenvatinib in elderly patients \u226580 years old with hepatocellular carcinoma: A multicenter observational study","volume":"29","author":"Kinoshita","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e250076","DOI":"10.1530\/EO-25-0076","article-title":"Real-world outcomes of lower lenvatinib doses in advanced neuroendocrine tumors: A multinational retrospective study","volume":"5","author":"Almeida","year":"2025","journal-title":"Endocr. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Shrem, N.S., Beltran-Bless, A.-A., Ghosh, S., Tajzler, C., Wood, L.A., Kollmannsberger, C., Basappa, N.S., Graham, J., Fallah-Rad, N., and Heng, D.Y. (2025). Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status Patients. Cancers, 17.","DOI":"10.3390\/cancers17030522"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ctrv.2016.04.002","article-title":"Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma","volume":"46","author":"Leliveld","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1200\/JCO.22.02622","article-title":"Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial","volume":"41","author":"Sternberg","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/bjc.2013.832","article-title":"Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma","volume":"110","author":"Hutson","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e847\u201359","DOI":"10.1016\/j.clgc.2019.05.003","article-title":"The Alternative 2\/1 Schedule of Sunitinib is Superior to the Traditional 4\/2 Schedule in Patients With Metastatic Renal Cell Carcinoma: A Meta-analysis","volume":"17","author":"Sun","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"102060","DOI":"10.1016\/j.clgc.2024.02.011","article-title":"Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis)","volume":"22","author":"Graham","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): Final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"102340","DOI":"10.1016\/j.jgo.2025.102340","article-title":"Pilot phase 2 study of the efficacy, safety, and tolerability of first-line cabozantinib for older fragile patients with metastatic renal cell carcinoma: The SOGUG-CABOMAYOR study","volume":"16","author":"Climent","year":"2025","journal-title":"J. Geriatr. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ctrv.2016.02.006","article-title":"Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis","volume":"45","author":"Nishijima","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40266-019-00697-2","article-title":"Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer","volume":"36","author":"Kapiteijn","year":"2019","journal-title":"Drugs Aging"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.10.032","article-title":"Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma","volume":"126","author":"Donskov","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1470-2045(19)30735-1","article-title":"Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): A phase 3, multicentre, randomised, controlled, open-label study","volume":"21","author":"Rini","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e16553","DOI":"10.1200\/JCO.2021.39.15_suppl.e16553","article-title":"TIVO-3: Age-related tolerability outcomes of tivozanib versus sorafenib in metastatic relapsed or refractory renal cell carcinoma, a subgroup analysis of the TIVO-3 clinical trial","volume":"39","author":"Escudier","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2011.02.014","article-title":"Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma","volume":"47","author":"Porta","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.eururo.2011.12.057","article-title":"Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: An exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial","volume":"61","author":"Porta","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Sibertin-Blanc, C., Norguet, E., Duluc, M., Louis, G., Seitz, J.-F., and Dahan, L. (2013). Severe hypersensitivity pneumonitis associated with everolimus therapy for neuroendocrine tumour: A case report. BMC Res. Notes, 6.","DOI":"10.1186\/1756-0500-6-471"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1200\/JCO.2011.39.7356","article-title":"Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway","volume":"30","author":"Busaidy","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.oraloncology.2011.08.009","article-title":"Clinical presentation and management of mTOR inhibitor-associated stomatitis","volume":"47","author":"Wang","year":"2011","journal-title":"Oral Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma","volume":"391","author":"Choueiri","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"S1308","DOI":"10.1016\/j.annonc.2025.08.3223","article-title":"2607P Belzutifan for advanced clear cell renal cell carcinoma (ccRCC) after a PD-(L)1 inhibitor and \u22652 VEGFR-TKIs in LITESPARK-005","volume":"36","author":"Jalkanen","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","article-title":"Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan: A phase 1 trial and biomarker analysis","volume":"27","author":"Choueiri","year":"2021","journal-title":"Nat. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_112","unstructured":"(2026, May 25). Belzutifan (Bel) Plus Lenvatinib (Lenva) Versus Cabozantinib (cabo) for Advanced Renal Cell Carcinoma (RCC) After Anti\u2013PD-(L)1 Therapy: Open-Label Phase 3 LITESPARK-011 Study\u2014ASCO. Available online: https:\/\/www.asco.org\/abstracts-presentations\/256659."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International Society of Geriatric Oncology Consensus on Geriatric Assessment in Older Patients With Cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/oncolo\/oyac119","article-title":"Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology","volume":"27","author":"Choucair","year":"2022","journal-title":"Oncologist"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_116","unstructured":"Howick, J., Chalmers, I., Glasziou, P., Greenhalgh, T., Heneghan, C., Liberati, A., Moschetti, I., Phillips, B., Thornton, H., and Goddard, O. (2026, July 01). The 2011 Oxford CEBM Levels of Evidence (Introductory Document); Oxford Centre for Evidence-Based Medicine. Available online: https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial","volume":"34","author":"Basch","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.clgc.2014.02.009","article-title":"Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population","volume":"12","author":"Khambati","year":"2014","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.eururo.2026.01.004","article-title":"KIM-1 and Circulating Tumor DNA Are Prognostic Markers for Oligometastatic Clear-cell Renal Cell Carcinoma: Development of a Multivariable Prognostic Model","volume":"89","author":"Tang","year":"2026","journal-title":"Eur. Urol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1080\/07853890.2021.1991591","article-title":"Systemic immune-inflammation index is a promising non-invasive biomarker for predicting the survival of urinary system cancers: A systematic review and meta-analysis","volume":"53","author":"Li","year":"2021","journal-title":"Ann. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6726\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:54:47Z","timestamp":1788242087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,30]]},"references-count":120,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15176726"],"URL":"https:\/\/doi.org\/10.3390\/jcm15176726","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,30]]}}}